All In Biotech

Drug Trial Radar · NCT04597125

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRPC) Progressing on/After One Line of ARPI

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 654 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

654

Actual

Start

Nov 9, 2020

Primary completion

Nov 21, 2025

Study completion Nov 19, 2026

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Oct 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and androgen receptor pathway inhibitor (ARPI) therapy work in participants with prostate gland cancer which has spread to the bone and progressed on or after one line of ARPI therapy. Meanwhile researchers want to compare the safety of radium-223 dichloride and ARPI therapy. Radium-223 dichloride is known as a radioactive drug that is taken up by bones after it is injected into the body. It works by giving off a type of radioactivity that travels a very short distance and kills the tumor cells that have spread to the bone without major effects to the healthy cells. It has been approved in many countries for the treatment of patients with prostate cancer which has spread to the bone. The ARPI drugs used in this study will be either abiraterone acetate (Zytiga) (plus prednisone/prednisolone) or enzalutamide (Xtandi). Both of them are standard approved medications which are used in the treatment of advanced prostate cancer. Participants in this study will receive either Radium-223 dichloride or a ARPI therapy. Radium-223 dichloride will be given as an infusion into one of the veins on Day 1 of each 4-week cycle for a total of up to 6 cycles. Oral ARPI therapy will be given per the standard approved dose once daily until the disease has progressed. Participants will visit the hospital or clinic every 2 weeks for the first 6 cycles, and only on the first day of each cycle from cycle 7 and onwards. Observation for each participant will last for about 2 years in total. Blood and urine samples will be collected from the participants and participants will be asked to complete questionnaires about the well-being and the pain.

Conditions

  • Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Interventions

  • Radium-223 dichloride (Xofigo, BAY88-8223)Drug

    Participants will receive Radium-223 (BAY88-8223) every 4 weeks for a total of 6 administrations via intravenous (IV) injection

  • ARPI therapyDrug

    Participants will receive continuous ARPI (either Abiraterone acetate plus prednisone/prednisolone \[AAP\] or enzalutamide) by mouth (per os) daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Up to five years

Locations

117 sites in 19 countries. Site status is shown where the registry gives one.

  • Specialist Services Medical Group

    Castle Hill, New South Wales, Australia

  • Gosford Hospital

    Gosford, New South Wales, Australia

  • Nepean Hospital

    Kingswood, New South Wales, Australia

  • North West Cancer Centre

    North Tamworth, New South Wales, Australia

  • Northern Cancer Institute

    St Leonards, New South Wales, Australia

  • Prince of Wales Hospital NSW

    Sydney, New South Wales, Australia

  • Illawarra Shoalhaven Local Health District

    Wollongong, New South Wales, Australia

  • Icon Cancer Care

    Brisbane, Queensland, Australia

  • Tasman Health Care

    Southport, Queensland, Australia

  • The Tweed Hospital

    Tugun, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Klinik Ottakring, Wilhelminenspital

    Vienna, Lower Austria, Austria

  • Kepler Universitätsklinikum GmbH

    Linz, Upper Austria, Austria

  • Krajská nemocnice Liberec, a. s.

    Liberec, Liberec Region, Czechia

  • Urocentrum Praha, s.r.o.

    Prague, Prague, Czechia

  • Všeobecná fakultní nemocnice v Praze

    Prague, Prague, Czechia

  • Fakultni Thomayerova Nemocnice

    Prague, Prague, Czechia

  • Fakultní nemocnice Bulovka

    Prague, Prague, Czechia

  • Fakultní nemocnice u sv. Anny v Brně

    Brno, South Moravian, Czechia

  • Krajska Zdravotní, a.s. - Nemocnice Chomutov, o.z. - Onkologické oddělení

    Chomutov, Ústí nad Labem Region, Czechia

  • Oulu University Hospital, Oulun yliopistollinen sairaala (OYS)

    Oulu, North Ostrobothnia, Finland

  • Tampere University Hospital, Tampereen yliopistollinen sairaala (TAYS)

    Tampere, Pirkanmaa, Finland

  • Seinäjoen keskussairaala

    Seinäjoki, South Ostrobothnia, Finland

  • OBSOLETE_Docrates Klinikka

    Helsinki, Uusimaa, Finland

  • Centre Hospitalier Universitaire - Grenoble

    La Tronche (Grenoble Area), Auvergne-Rhône-Alpes, France

  • Unicancer Dijon - Centre Georges Francois Leclerc

    Dijon, Bourgogne-Franche-Comté, France

  • Hôpital Morvan - Brest

    Brest, Brittany Region, France

  • Centre Eugène Marquis - Rennes Cedex

    Rennes, Brittany Region, France

  • Institut de Cancerologie Jean Godinot

    Reims, Grand Est, France

  • CHU Strasbourg - Hopital Hautepierre

    Strasbourg, Grand Est, France

  • Institut de Cancérologie de Lorraine - Alexis Vautrin

    Vandœuvre-lès-Nancy, Grand Est, France

  • Hôpital Henri Mondor

    Créteil, Île-de-France Region, France

  • Gustave Roussy - Departement Oncologie-Radiotherapie

    Villejuif, Île-de-France Region, France

  • CHU de Bordeaux - Hopital Saint Andre

    Bordeaux, New Aquitaine, France

  • Centre de Lutte Contre le Cancer François Baclesse

    Caen, Normandy, France

  • Unicancer Marseille - Institut Paoli-Calmettes

    Marseille, Provence-Alpes-Côte d'Azur Region, France

  • Centre Antoine Lacassagne Nice

    Nice, Provence-Alpes-Côte d'Azur Region, France

  • Universitätsklinikum Münster

    Münster, North Rhine-Westphalia, Germany

  • Universitätsmedizin der Johannes Gutenberg, Universität Mainz

    Mainz, Rhineland-Palatinate, Germany

  • Pamela Youde Nethersole Eastern Hospital

    Chai Wan, Hong Kong Island, Hong Kong

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.